| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Twelve haemophiliacs with chronic hepatitis C, all infected with genotype 1b, were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. Sustained virologic response was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy prematurely.
- Twelve haemophiliacs with chronic hepatitis C, all infected with genotype 1b, were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. Sustained virologic response was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy prematurely. (en)
- Dvanáct hemofiliků s chronickou hepatitidou C, všichni infikovaní genotypem 1b, bylo léčeno interferonem (IFN) alfa v monoterapii, 21 kombinací IFN alfa a ribavirinu a 3 pegylovaným IFN a ribavirinem Setrvalé virologické odpovědi nedosáhl žádný z 12 pacientů léčených samotným IFN. Kombinovaná léčba IFN a ribavirinem byla úspěšnější: 4/10 (40%) dosud neléčených pacientů, 2/4 (50%) relapserů a 2/7 (29%) non-responderů dosáhlo setrvalé virologické odpovědi, stejně tak byla úspěšná kombinované léčba pegylovaným IFN a ribavirinem u jediného pacienta relabujícího po monoterapii IFN a jednoho ze dvou non-responderů na tuto monoterapii. Nebyly zaznamenány závažné nežádoucí účinkya nebylo nutné redukovat dávku použitých léků nebo předčasně ukončit léčbu. Úspěšnost a snášenlivost antivirové léčby byla u hemofiliků stejná jako u jiných pacientů s chronickou hepatitidou C. (cs)
|
| Title
| - Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens.
- Úspěšnost a bezpečnost léčby chronické hepatitidy C u hemofiliků. (cs)
- Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens. (en)
|
| skos:prefLabel
| - Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens.
- Úspěšnost a bezpečnost léčby chronické hepatitidy C u hemofiliků. (cs)
- Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens. (en)
|
| skos:notation
| - RIV/65269705:_____/05:#0000001!RIV06-MZ0-65269705
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/65269705:_____/05:#0000001
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Chronic hepatitis C; Haemophilia; Interferon-alfa; Pegylated interferon; Ribavirin (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| |
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Husa, Petr
- Penka, Miroslav
- Rožnovský, Luděk
- Husová, Libuše
- Smejkal, Petr
|
| issn
| |
| number of pages
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)